S66 Table. Summary of Findings

| **Tocilizumab + favipiravir compared with tocilizumab for COVID-19** |
| --- |
| **Patients or population:** Anyone with a diagnosis of COVID-19**Setting:** Any setting**Intervention**: Tocilizumab +favipiravir**Comparison:** Tocilizumab |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | **Relative effect (95% CI)** | **No of participants(studies)** | **Certainty of the evidence (GRADE)** | **Comments** |
| **Risk with** **tocilizumab** | **Risk with****Tocilizumab + favipiravir** |
| **All-cause mortality***Follow-up: unclear* | 0 per 1.000 | **0 per 1.000** | - | 19(1 RCT) | ⨁◯◯◯VERY LOW a,b,c | Zero events in both groups. Zero numbers analyzed in two studies. |
| **Serious adverse events***Follow-up: unclear* | 0 per 1.000 | **0 per 1.000** | - | 19(1 RCT) | ⨁◯◯◯VERY LOW a,b,c | Zero numbers analyzed in two studies. |
| **Admission to intensive care** | - | - | - | - | - | Outcome not yet measured or reported |
| **Mechanical ventilation***Follow-up: unclear* | 0 per 1.000 | **0 per 1.000** | - | 19(1 RCT) | ⨁◯◯◯VERY LOW a,b,c | Zero events in both groups. Zero numbers analyzed in two studies. |
| **Renal replacement therapy** | - | - | - | - | - | Outcome not yet measured or reported |
| **Quality of Life** | - | - | - | - | - | Outcome not yet measured or reported |
| **Non-serious adverse events** | - | - | - | - | - | Outcome not yet measured or reported |
| **RR:** Risk ratio; **CI:** Confidence interval; **GRADE:** GRADE Working Group grades of evidence |
| **GRADE Working Group grades of evidence****High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect |

**Explanations**

a. Downgraded 2 for risk of bias

b. Downgraded 2 for imprecision due to low number of participants